Humana Inc. (NYSE:HUM) Shares Sold by Jump Financial LLC

Jump Financial LLC lowered its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 84.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,416 shares of the insurance provider's stock after selling 41,121 shares during the quarter. Jump Financial LLC's holdings in Humana were worth $1,882,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Adams Wealth Management grew its stake in shares of Humana by 24.3% during the fourth quarter. Adams Wealth Management now owns 9,717 shares of the insurance provider's stock valued at $2,465,000 after acquiring an additional 1,899 shares in the last quarter. AGP Franklin LLC acquired a new position in Humana in the 4th quarter worth about $1,506,000. Canada Post Corp Registered Pension Plan acquired a new position in Humana during the fourth quarter valued at approximately $271,000. Baupost Group LLC MA bought a new position in Humana during the fourth quarter worth $87,784,000. Finally, Mariner LLC boosted its position in shares of Humana by 4.0% during the 4th quarter. Mariner LLC now owns 13,461 shares of the insurance provider's stock valued at $3,415,000 after purchasing an additional 517 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Trading Up 0.4 %

Shares of NYSE HUM traded up $1.19 during mid-day trading on Thursday, reaching $264.80. 223,503 shares of the company's stock were exchanged, compared to its average volume of 1,751,700. The firm has a market capitalization of $31.96 billion, a price-to-earnings ratio of 26.65, a PEG ratio of 2.05 and a beta of 0.62. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The company's 50-day moving average is $265.94 and its 200-day moving average is $270.14.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date is Friday, June 27th. Humana's dividend payout ratio is presently 35.58%.

Wall Street Analyst Weigh In

HUM has been the subject of several research reports. Guggenheim assumed coverage on shares of Humana in a research report on Wednesday, April 9th. They set a "buy" rating and a $326.00 price target for the company. Barclays lifted their price target on shares of Humana from $270.00 to $322.00 and gave the stock an "equal weight" rating in a research note on Friday, April 11th. Piper Sandler lifted their price target on shares of Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a research note on Wednesday, January 15th. JPMorgan Chase & Co. cut their target price on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a report on Tuesday, February 18th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $284.90.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.